MX2019011649A - Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazoli n-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol. - Google Patents

Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazoli n-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.

Info

Publication number
MX2019011649A
MX2019011649A MX2019011649A MX2019011649A MX2019011649A MX 2019011649 A MX2019011649 A MX 2019011649A MX 2019011649 A MX2019011649 A MX 2019011649A MX 2019011649 A MX2019011649 A MX 2019011649A MX 2019011649 A MX2019011649 A MX 2019011649A
Authority
MX
Mexico
Prior art keywords
pyridazin
morpholin
fluoro
chloro
methoxy
Prior art date
Application number
MX2019011649A
Other languages
English (en)
Inventor
Fuchss Thomas
Kuehn Clemens
Poma Marco
Burini Edoardo
Lange Michael
Maillard David
BREUNING Marcel
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2019011649A publication Critical patent/MX2019011649A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a (S)-[2-cloro-4-fluoro-5-(7-morf olin-4-ilquinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol cristalino desordenado anhidro, así como un método para producir el mismo, y composiciones farmacéuticas y usos médicos del mismo.
MX2019011649A 2017-03-30 2018-03-28 Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazoli n-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol. MX2019011649A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163826 2017-03-30
PCT/EP2018/057875 WO2018178133A1 (en) 2017-03-30 2018-03-28 Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol

Publications (1)

Publication Number Publication Date
MX2019011649A true MX2019011649A (es) 2019-12-19

Family

ID=58461171

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011649A MX2019011649A (es) 2017-03-30 2018-03-28 Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazoli n-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.

Country Status (16)

Country Link
US (1) US11053233B2 (es)
EP (1) EP3601265B1 (es)
JP (1) JP7365904B2 (es)
KR (1) KR20190136037A (es)
CN (1) CN110446705B (es)
AU (1) AU2018246257B2 (es)
CA (1) CA3058285C (es)
DK (1) DK3601265T3 (es)
ES (1) ES2956036T3 (es)
IL (1) IL269667B1 (es)
MX (1) MX2019011649A (es)
RU (1) RU2019133577A (es)
SG (1) SG11201909059XA (es)
TW (1) TWI781161B (es)
WO (1) WO2018178133A1 (es)
ZA (1) ZA201907144B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
WO2018178129A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
WO2020259613A1 (zh) 2019-06-27 2020-12-30 南京明德新药研发有限公司 作为dna-pk抑制剂的喹啉和噌啉衍生物
WO2022143671A1 (zh) * 2020-12-28 2022-07-07 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (es) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
AU2008215411B2 (en) * 2007-02-16 2012-11-22 Eisai R & D Management Co., Ltd. Crystal, amorphous form and salt of methyl N-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
WO2009100258A1 (en) * 2008-02-05 2009-08-13 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical solid state forms
IT1404157B1 (it) * 2010-12-30 2013-11-15 Nano Active Film S R L Forma cristallina nanoporosa disordinata di polistirene sindiotattico, suo processo di preparazione e articoli comprendenti la stessa.
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
DK3003309T3 (da) * 2013-05-30 2020-12-14 Infinity Pharmaceuticals Inc Behandling af cancer med PI3-kinase-isoform modulatorer
US10905146B2 (en) * 2013-07-12 2021-02-02 The Coca-Cola Company Compositions for improving rebaudioside M solubility
AU2016275125A1 (en) * 2015-06-12 2018-01-25 Gb006, Inc. Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Also Published As

Publication number Publication date
AU2018246257B2 (en) 2022-05-12
EP3601265A1 (en) 2020-02-05
RU2019133577A3 (es) 2021-07-30
ES2956036T3 (es) 2023-12-12
IL269667B1 (en) 2024-05-01
US20200123144A1 (en) 2020-04-23
ZA201907144B (en) 2023-10-25
AU2018246257A1 (en) 2019-11-14
CA3058285A1 (en) 2018-10-04
JP7365904B2 (ja) 2023-10-20
EP3601265B1 (en) 2023-06-21
SG11201909059XA (en) 2019-10-30
US11053233B2 (en) 2021-07-06
RU2019133577A (ru) 2021-04-30
CN110446705B (zh) 2023-04-14
CN110446705A (zh) 2019-11-12
CA3058285C (en) 2024-02-06
JP2020512362A (ja) 2020-04-23
TW201900634A (zh) 2019-01-01
KR20190136037A (ko) 2019-12-09
AU2018246257A8 (en) 2019-11-28
DK3601265T3 (da) 2023-09-18
WO2018178133A1 (en) 2018-10-04
TWI781161B (zh) 2022-10-21
IL269667A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
ZA201907144B (en) Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
PH12018500457A1 (en) New phenoxymethyl derivatives
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2017014035A (es) Formas solidas novedosas.
PH12015500263A1 (en) New bicyclic derivatives
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
NZ766570A (en) Pyrimidinones as factor xia inhibitors
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MY194116A (en) Pharmaceutical compounds
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MY197698A (en) Oxysterols and methods of use thereof
MX2018002217A (es) Nuevos compuestos biciclicos como inhibidores de autotaxina (atx).
JO3155B1 (ar) معدِّل نكهة حلوة
MY169267A (en) New aryl-quinoline derivatives
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
CY1122506T1 (el) Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
PH12020550592A1 (en) Process for producing herbicidal pyridazinone compounds
WO2018039077A8 (en) Therapeutic compounds
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
MX2019011639A (es) Formulacion farmaceutica.